Sunshine Lake Pharma Co., Ltd. (HKG:6887)

Market Cap	21.05B -32.3%
Revenue (ttm)	4.56B +28.4%
Net Income	-328.92M
EPS	-0.60
Shares Out	575.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	5.69 (15.75%)
Ex-Dividend Date	Jul 31, 2025

Volume	407,116
Open	36.00
Previous Close	36.58
Day's Range	35.98 - 36.98
52-Week Range	15.01 - 54.25
Beta	-0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About Sunshine Lake Pharma

Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien and Dongyinghe for the treatment of hepatitis C. The company also engages in the import, export, wholesale, retail, and distribution of pharmaceutical products, intermediates, and active pharmaceutical ingredients; product quality inspection; research and development of biosimilar drugs and new biol...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 6,299
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6887

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error